BR112016029994A2 - métodos de preparação de análogos de nucleotídeo substituídos - Google Patents

métodos de preparação de análogos de nucleotídeo substituídos

Info

Publication number
BR112016029994A2
BR112016029994A2 BR112016029994A BR112016029994A BR112016029994A2 BR 112016029994 A2 BR112016029994 A2 BR 112016029994A2 BR 112016029994 A BR112016029994 A BR 112016029994A BR 112016029994 A BR112016029994 A BR 112016029994A BR 112016029994 A2 BR112016029994 A2 BR 112016029994A2
Authority
BR
Brazil
Prior art keywords
methods
nucleotide analogs
preparing substituted
substituted nucleotide
preparing
Prior art date
Application number
BR112016029994A
Other languages
English (en)
Inventor
Beigelman Leonid
Serebryany Vladimir
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of BR112016029994A2 publication Critical patent/BR112016029994A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

a presente invenção refere-se a métodos de preparação de um análogo de nucleotídeo de fosforoamidato, o qual é útil no tratamento de doenças e/ou condições tais como infecções virais.
BR112016029994A 2014-06-24 2015-06-22 métodos de preparação de análogos de nucleotídeo substituídos BR112016029994A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016229P 2014-06-24 2014-06-24
PCT/US2015/036989 WO2015200216A1 (en) 2014-06-24 2015-06-22 Methods of preparing substituted nucleotide analogs

Publications (1)

Publication Number Publication Date
BR112016029994A2 true BR112016029994A2 (pt) 2017-08-22

Family

ID=54869042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029994A BR112016029994A2 (pt) 2014-06-24 2015-06-22 métodos de preparação de análogos de nucleotídeo substituídos

Country Status (17)

Country Link
US (1) US20150368286A1 (pt)
EP (1) EP3160979A4 (pt)
JP (1) JP2017519779A (pt)
KR (1) KR20170026494A (pt)
CN (1) CN106661076A (pt)
AU (1) AU2015280245A1 (pt)
BR (1) BR112016029994A2 (pt)
CA (1) CA2952812A1 (pt)
CL (1) CL2016003277A1 (pt)
EA (1) EA201692473A1 (pt)
IL (1) IL249456A0 (pt)
MX (1) MX2016017382A (pt)
NZ (1) NZ727392A (pt)
PH (1) PH12016502555A1 (pt)
SG (1) SG11201610259SA (pt)
TW (1) TW201625659A (pt)
WO (1) WO2015200216A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013361193B2 (en) 2012-12-21 2018-05-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
DK3013843T3 (en) 2013-06-26 2018-09-03 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
EP3160475B1 (en) 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides and nucleotides to treat filoviridae infections
DK3160476T3 (da) 2014-06-24 2020-12-21 Janssen Biopharma Inc Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
WO2019237297A1 (en) * 2018-06-14 2019-12-19 Janssen Pharmaceuticals, Inc. Processes for preparing compounds/intermediates useful in the treatment of viral infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817978A (en) * 1971-06-16 1974-06-18 Syntex Inc 4-fluoro nucleosides and sugar intermediates, and methods of preparing
AU2013266393B2 (en) * 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP3421482A1 (en) * 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MY186547A (en) * 2013-05-16 2021-07-26 Riboscience Llc 4?-fluoro-2?-methyl substituted nucleoside derivatives
TW201542578A (zh) * 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
TW201524990A (zh) * 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
WO2016069489A1 (en) * 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci

Also Published As

Publication number Publication date
JP2017519779A (ja) 2017-07-20
NZ727392A (en) 2018-04-27
CN106661076A (zh) 2017-05-10
MX2016017382A (es) 2017-04-27
IL249456A0 (en) 2017-02-28
US20150368286A1 (en) 2015-12-24
SG11201610259SA (en) 2017-01-27
KR20170026494A (ko) 2017-03-08
EP3160979A1 (en) 2017-05-03
CL2016003277A1 (es) 2017-06-02
PH12016502555A1 (en) 2017-04-10
TW201625659A (zh) 2016-07-16
CA2952812A1 (en) 2015-12-30
AU2015280245A1 (en) 2017-01-05
EA201692473A1 (ru) 2017-03-31
EP3160979A4 (en) 2018-01-03
WO2015200216A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
BR112016029994A2 (pt) métodos de preparação de análogos de nucleotídeo substituídos
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
NI201700019A (es) Anticuerpos anti tigit
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
BR112016028045A8 (pt) biopolímeros modificados, e seus métodos de produção
BR112019002357A2 (pt) purificação de matéria-prima por tratamento térmico
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
UY37360A (es) Nucleósidos sustituidos, nucleótidos y análogos de estos
BR112017007012A2 (pt) compostos anti-tnf
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
NZ630800A (en) Methods of preparing substituted nucleotide analogs
BR112018012174A2 (pt) moduladores da atividade de complemento
BR112017008672A2 (pt) anticorpos de il-6 melhorados
MX2016014765A (es) Incremento del rendimiento utilizando soforolipidos.
MX2018005872A (es) Profarmacos de acido nucleico.
CR20160428A (es) Pizazinas moduladoras de gpr6
BR112017009503A2 (pt) composição farmacêutica parenteral de ação prolongada, métodos para tratar, para prevenir e para curar uma infecção por hcv, e, kit.
BR112017003437A2 (pt) processo para a preparação e/ou purificação de cloreto de rutênio(iii)
AR120118A2 (es) Anticuerpos anti tigit
TH168570B (th) วิธีการของการเตรียมนิวคลิโอไทด์อนาล็อกที่ถูกแทนที่

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.